MedPath

Cubicin

These highlights do not include all the information needed to use CUBICIN safely and effectively. See full prescribing information for CUBICIN. CUBICIN (daptomycin for injection), for Intravenous UseInitial U.S. Approval: 2003

Approved
Approval ID

a7975871-46a6-4e9b-a8b5-38bfcb465f0e

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 24, 2023

Manufacturers
FDA

Merck Sharp & Dohme LLC

DUNS: 118446553

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Daptomycin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code67919-011
Application NumberNDA021572
Product Classification
M
Marketing Category
C73594
G
Generic Name
Daptomycin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 22, 2022
FDA Product Classification

INGREDIENTS (2)

DaptomycinActive
Quantity: 500 mg in 10 mL
Code: NWQ5N31VKK
Classification: ACTIB
Sodium HydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.